Overview
- IndustryEngines & Turbines1
- HeadquartersBellevue, Washington1
- Incorporated inNV3
- Business address11120 Ne 2Nd Street, Suite 100, Bellevue, Wa 980043
- Filer categoryNon-accelerated filer, Smaller reporting company3
See how the biggest companies compare on our leaderboards
(iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
Where the money goes
Where each dollar of revenue went, fiscal 2024
- Cost of revenue57¢$7.6M
- Other costs38¢$5.1M
- Interest5¢$652.4K
Out of $13.3M in revenue.2 The company lost money this year.
Financial statements
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.0M6 | $8.9M7 | $9.4M8 | $7.9M9 | $9.3M10 | $11.7M11 | $12.6M2 | $13.3M2 |
| Cost of revenue | $5.0M6 | $5.5M7 | $5.9M8 | $4.8M9 | $5.5M10 | $6.9M11 | $7.6M2 | $7.6M2 |
| Gross profit | $3.0M6 | $3.4M7 | $3.5M8 | $3.1M9 | $3.8M10 | $4.8M11 | $5.0M2 | $5.7M2 |
| Research and development | ||||||||
| Operating expenses | $29.8M11 | $13.5M2 | $15.8M2 | |||||
| Operating income | -$113.0K6 | -$1.6M7 | -$785.6K8 | -$4.3M9 | -$4.4M10 | -$25.0M11 | -$8.6M2 | -$10.1M2 |
| Interest | $554.7K6 | $564.5K6 | $222.2K8 | $156.7K9 | $165.0K10 | $1.6M11 | $360.6K2 | $652.4K2 |
| Income before tax | -$33.1M11 | -$13.3M2 | -$16.1M2 | |||||
| Income tax | $111.7K6 | -$22.3K11 | ||||||
| Net income | -$738.4K6 | -$2.1M7 | -$392.0K8 | -$4.9M9 | -$4.5M10 | -$32.8M11 | -$13.2M2 | -$16.2M2 |
| Earnings per share | -$0.1810 | -$11.2811 | -$1.302 | -$0.892 | ||||
| Earnings per share (diluted) | -$11.2811 | -$1.302 | -$0.892 | |||||
| Shares (weighted, basic) | 2.9M shares11 | 10.2M shares2 | 18.0M shares2 | |||||
| Shares (weighted, diluted) | 2.9M shares11 | 10.2M shares2 | 18.0M shares2 |
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash | $1.9M6 | $675.7K7 | $2.1M8 | $2.1M9 | $8.3M10 | $2.2M11 | $416.3K2 | $844.6K2 |
| Receivables | $1.0M11 | $1.5M2 | $1.9M2 | |||||
| Inventory | $879.0K11 | $1.1M2 | $1.0M2 | |||||
| Current assets | $3.7M6 | $2.6M7 | $4.1M8 | $4.3M9 | $11.1M10 | $5.7M11 | $4.4M2 | $5.4M2 |
| Property, plant and equipment | $5.8M11 | $5.4M2 | $5.1M2 | |||||
| Goodwill | $7.8M2 | $7.6M2 | $6.6M2 | |||||
| Intangible assets | $18.8M11 | $16.2M2 | $13.4M2 | |||||
| Total assets | $5.5M6 | $4.7M7 | $32.3M8 | $35.4M9 | $62.0M10 | $40.9M11 | $35.6M2 | $32.1M2 |
| Accounts payable | $1.8M11 | $3.5M2 | $3.2M2 | |||||
| Current liabilities | $4.3M6 | $3.3M7 | $3.0M8 | $2.6M9 | $8.5M10 | $14.1M11 | $7.9M2 | $14.6M2 |
| Long-term debt | $427.5K14 | $9.6M9 | $161.5K10 | $342.4K11 | $157.7K2 | |||
| Total liabilities | $9.8M6 | $4.6M7 | $6.7M8 | $5.8M9 | $18.2M10 | $18.8M11 | $11.1M2 | $17.5M2 |
| Retained earnings | -$53.8M11 | -$67.0M2 | -$83.2M2 | |||||
| Shareholders’ equity | -$4.3M6 | $201.4K7 | $25.6M8 | $29.6M9 | $43.9M10 | $22.3M11 | $24.8M2 | $14.9M2 |
| Shares outstanding | 202.2M shares14 | 207.9M shares6 | 224.0M shares7 | 235.5M shares8 | 28.6M shares9 | 3.1M shares11 | 17.3M shares11 | 19.7M shares2 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -$810.7K6 | -$934.5K7 | -$822.3K8 | -$441.7K9 | -$1.0M10 | -$5.9M11 | -$2.2M2 | -$5.1M2 |
| Depreciation and amortization | $3.0M11 | $2.3M2 | $2.3M2 | |||||
| Stock-based compensation | $426.7K11 | $385.3K2 | $147.7K2 | |||||
| Capital spending | $38.2K6 | $178.6K7 | $107.6K8 | $12.1K9 | $255.9K10 | $190.2K11 | $49.2K2 | $5.0K2 |
| Free cash flow | -$848.9K | -$1.1M | -$929.9K | -$453.8K | -$1.3M | -$6.1M | -$2.3M | -$5.1M |
| Cash from investing | $163.5K11 | -$49.2K2 | -$5.0K2 | |||||
| Cash from financing | -$427.1K11 | $763.9K2 | $5.0M2 |
Corporate structure
Novo Integrated Sciences, Inc. sits at the top of its group. 11 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Novo Integrated Sciences, Inc.
- Hudson Bay Capital Management LP Filed SC 13G/A on Novo Integrated Sciences, Inc., latest Feb 6, 2024 (4 filings since Feb 8, 2022)
- Novo Integrated Sciences, Inc. Bellevue, Washington
- 12858461 Canada Corp. Subsidiary · Canada
- Acenzia, Inc. Subsidiary · Ontario, Canada
- Clinical Consultants International LLC Subsidiary · Delaware, United States
- Novo Assessments Inc. Subsidiary · Ontario, Canada
- Novo Healthnet Kemptville Centre, Inc. Subsidiary · Ontario, Canada
- Novo Healthnet Limited Subsidiary · Ontario, Canada
- Novo Healthnet Rehab Limited Subsidiary · Ontario, Canada
- Novomerica Health Group, Inc. Subsidiary · Nevada, United States
- PRO-DIP, LLC Subsidiary · New York, United States
- Terragenx Inc. Subsidiary · Canada
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Novo Integrated Sciences, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $6.5M2 Aug 31, 2024 | $6.6M2 Aug 31, 2023 | −1.4% |
| Accumulated depreciation | $1.4M2 Aug 31, 2024 | $1.3M2 Aug 31, 2023 | +14.8% |
| Property and equipment, net | $5.1M2 Aug 31, 2024 | $5.4M2 Aug 31, 2023 | −5.2% |
| Operating-lease assets (leased space) | $1.7M2 Aug 31, 2024 | $2.0M2 Aug 31, 2023 | −14.7% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $844.6K2 Aug 31, 2024 | $416.3K2 Aug 31, 2023 | +102.9% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $6.6M2 Aug 31, 2024 | $7.6M2 Aug 31, 2023 | −13.6% |
| Intangible assets, net (excluding goodwill) | $13.4M2 Aug 31, 2024 | $16.2M2 Aug 31, 2023 | −17.6% |
| Finite-lived intangibles, gross | $22.4M2 Aug 31, 2024 | $23.3M2 Aug 31, 2023 | −4.0% |
| Accumulated amortization | $9.0M2 Aug 31, 2024 | $7.1M2 Aug 31, 2023 | +27.2% |
| Finite-lived intangibles, net | $13.4M2 Aug 31, 2024 | $16.2M2 Aug 31, 2023 | −17.6% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $1.0M2 Aug 31, 2024 | $1.1M2 Aug 31, 2023 | −9.6% |
| Raw materials | $227.5K2 Aug 31, 2024 | $388.4K2 Aug 31, 2023 | −41.4% |
| Work in process | $225.1K2 Aug 31, 2024 | $81.7K2 Aug 31, 2023 | +175.5% |
| Finished goods | $548.2K2 Aug 31, 2024 | $636.9K2 Aug 31, 2023 | −13.9% |
Properties, in its own words
We currently maintain a corporate address at 11120 NE 2nd Street, Suite 100, Bellevue, Washington 98004. Our telephone number there is (206) 617-9797. We pay no rent or other fees for the use of the Company’s corporate address.
Our wholly owned subsidiary, Novo Healthnet Limited, has corporate offices located at 3905 Major MacKenzie Drive, Suite 115, Vaughan Ontario Canada L4H 4J9. This location is approximately 1,160 square feet. The lease expires on June 30, 2027. Terms of the lease provide for a base rent payment of CAD$3,059 (including HST) (approximately $2,248 as of August 31, 2024) per month.
The rest of Item 2
Novo Healthnet Limited currently operates our 14 corporate-owned clinics through standard tenancy agreements out of leased properties located at:
(1) · Novo Healthnet Limited (Niagara Falls)
4056 Dorchester Rd., Suites 104 & 105, Niagara Falls, Ontario L2E 6M9, Canada;
(2) · Novo Healthnet Limited (Windsor)
250 Tecumseh Rd. E., Building 100, Unit 150, Windsor, Ontario N8X 2R3, Canada;
(3) · Back on Track Physio & Health Centres (Scarborough)
8 Glen Watford Drive, Unit G3-G5, Scarborough, Ontario M1S 2C1, Canada;
(4) · Back On Track Physio & Health Centres (Antares)
6 Antares Drive Ph 1, Unit 3, Nepean, Ontario K2E 8A9, Canada;
(5) · Back On Track Physio & Health Centres (Richmond Oaks)
6265 Perth St, Richmond, Ontario K0A 2Z0, Canada;
(6) · Back On Track Physio & Health Centres (Hunt Club)
380 Hunt Club Rd. Suite 107, Ottawa, Ontario K1V 1C1, Canada;
(7) · Back On Track Physio & Health Centres (Findlay Creek)
4744 Bank Street, Unit 2, Gloucester, Ontario K1T 0K8, Canada;
(8) · Back On Track Physio & Health Centres (Bells Corners)
2006 Robertson Rd., Unit 2, Nepean, Ontario K2H 1A5, Canada;
(9) · Back On Track Physio & Health Centres (Manotick)
5230B Mitch Owens Road, Manotick, Ontario K4M 1B2, Canada;
(10) · Back On Track Physio & Health Centres (Carleton Place)
515 McNeely Drive, Unit 3, Carleton Place, Ontario K7C 0A8, Canada;
(11) · Back On Track Physio & Health Centres (Kemptville)
301 Rideau Street, Kemptville, Ontario K0G 1J0, Canada;
(12) · Back On Track Physio & Health Centres (Perth)
9 Eric Devlin Lane. Unit 100, Perth, Ontario K7H 0C4, Canada;
(13) · Back On Track Physio & Health Centres (Rockland)
2741 Chamberland St., Unit 208 Rockland, Ontario K4K 0B8 Canada.
(14) · Fairway Physiotherapy – NovaCare
1600 Dease St. Thunder Bay, Ontario P7C 5H4 Canada
NHL leases premises for the foregoing 14 corporate-owned clinics, ranging in terms of 0 to 8 years with monthly lease rates ranging from CAD$904 (approximately $665 as of August 31, 2024 to CAD$11,065 (approximately $8,132 as of August 31, 2024). The aggregate monthly rent for the corporate-owned clinic properties is CAD$103,650 (approximately $76,172 as of August 31, 2024). Two of the leases are month-to-month with 30-days’ notice for either party and the remaining 12 corporate-owned clinic leases have expiration dates between 2027 and 2031.
We believe that these facilities are suitable and adequate for our current operations.
Item 2 of the 10-K filed Dec 18, 2024.5
Leadership
Who has led Novo Integrated Sciences, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief operating officer
- Chief executive officerRobert Mattacchione Feb 19, 2021 to Feb 19, 202115
- Chief executive officerMichael Rouse Feb 17, 2006 to Oct 25, 200716
- ChairMichael Rouse Feb 17, 2006 to Oct 25, 200716
- PresidentChristopher Mehlin David Feb 19, 2021 to Jun 2, 202317
- Chief operating officerChristopher Mehlin David Jun 2, 2023 to Sep 12, 202418
Board members and other officers (8)
- Principal Financial OfficerSterling M. Jimenez Apr 28, 2021 to Apr 28, 202119
- Board memberSarfaraz Ali Aug 10, 2022 to Aug 10, 202220
- Board memberAlex Flesias Feb 19, 2021 to Feb 24, 202221
- Board memberChristopher Mehlin David Feb 19, 2021 to Sep 12, 202417
- Board memberMichael Joseph Gaynor Feb 19, 2021 to Feb 19, 202122
- Board memberPierre Joseph Dalcourt Feb 19, 2021 to Feb 19, 202123
- Board memberRobert Letterio Oliva Feb 19, 2021 to Apr 21, 202224
- Board memberRobert Mattacchione Feb 19, 2021 to Feb 19, 202115
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- 12858461 Canada Corp. Canada4
- Acenzia, Inc. Ontario, Canada4
- Clinical Consultants International LLC Delaware4
- Novo Assessments Inc. Ontario, Canada4
- Novo Healthnet Kemptville Centre, Inc. Ontario, Canada4
- Novo Healthnet Limited Ontario, Canada4
- Novo Healthnet Rehab Limited Ontario, Canada4
- Novomerica Health Group, Inc. Nevada4
- PRO-DIP, LLC New York4
- Terragenx Inc. Canada4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- TURBINE TRUCK ENGINES INCSep 25, 2003 to Jul 12, 20173
Timeline
- May 6, 20258-K Executive or director change25
- May 2, 20258-K Listing notice or transfer26
- Apr 4, 20258-K Executive or director change27
- Mar 11, 20258-K Executive or director change28
- Feb 25, 20258-K Executive or director change29
- Feb 11, 20258-K Executive or director change30
- Dec 18, 20248-K Results of operations31
- Nov 29, 20248-K Shareholder vote32
- Nov 20, 20248-K Other events33
- Nov 14, 20248-K Executive or director change; Other events34
- Nov 6, 20248-K Listing notice or transfer35
- Oct 31, 20248-K Executive or director change36
- Feb 19, 2021New chief executive Robert Mattacchione becomes CEO15
- Feb 17, 2006New chief executive Michael Rouse becomes CEO16
Calendar
When it reported results
- Dec 18, 2024Reported quarterly or annual results31
- Jul 19, 2024Reported quarterly or annual results37
- Apr 15, 2024Reported quarterly or annual results38
- Jan 22, 2024Reported quarterly or annual results39
- Dec 14, 2023Reported quarterly or annual results40
- Jul 17, 2023Reported quarterly or annual results41
- May 26, 2023Reported quarterly or annual results42
- May 24, 2023Reported quarterly or annual results43
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
181 filings to the SEC since October 2021: 4 annual reports, 9 quarterly reports, 113 major events, 8 insider forms, 4 large holders, 43 other. The latest 20:
- May 20, 2025SEC STAFF ACTION EDGAR
- May 19, 202525-NSE EDGAR
- May 6, 20258-K EDGAR
- May 2, 20258-K EDGAR
- Apr 4, 20258-K EDGAR
- Mar 11, 20258-K EDGAR
- Feb 25, 20258-K EDGAR
- Feb 11, 20258-K EDGAR
- Jan 14, 2025NT 10-Q EDGAR
- Dec 18, 202410-K EDGAR
- Dec 18, 20248-K EDGAR
- Nov 29, 2024NT 10-K EDGAR
- Nov 29, 20248-K EDGAR
- Nov 20, 2024DEFA14A EDGAR
- Nov 20, 20248-K EDGAR
- Nov 14, 2024DEFA14A EDGAR
- Nov 14, 20248-K EDGAR
- Nov 6, 20248-K EDGAR
- Oct 31, 20248-K EDGAR
- Oct 23, 20248-K EDGAR
The 181 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Apr 20, 2022 | Oliva Robert LetterioDirector | Buy | 5,000 | $2.23 | $11.2K | Form 4 |
| Apr 19, 2022 | Oliva Robert LetterioDirector | Buy | 5,000 | $2.23 | $11.2K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Hudson Bay Capital Management LPSC 13G/A, 4 filings Feb 8, 2022 to Feb 6, 202444
SEC filer profile
How Novo Integrated Sciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARNovo Integrated Sciences, Inc.1
- CIK0001138978
- Employer ID (EIN)59-36916505
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company5
- Incorporated inNevada5
- Fiscal year endsAugust 311
- Industry code (SIC)3510 Engines & Turbines1
- SEC reviewing officeOffice of Technology, Division of Corporation Finance1
- Business address11120 Ne 2Nd Street, Suite 100, Bellevue, WA 980041
- Phone(206) 617-97971
- Shares outstanding19,730,247 shares as of Dec 17, 20245
- Public float$10.2M as of Feb 29, 20245
- AuditorFruci & Associates II, PLLC, Spokane, Washington PCAOB ID 5525; no auditor attestation of internal control over financial reporting5
- On EDGAR sinceSep 25, 20031
- Filings485 in all: 8-K (230), 10-Q (50), 4 (29), 3 (18), 10-K (17), NT 10-Q (16), NT 10-K (12), 10QSB (11)1
All 50 form types
CORRESP (9), S-8 (9), UPLOAD (9), DEFA14A (6), 8-K/A (5), SB-2/A (5), 10KSB (4), EFFECT (4), 10-Q/A (3), DEF 14A (3), S-3 (3), 3/A (2), 424B5 (2), 5 (2), DEF 14C (2), POS AM (2), PRE 14A (2), PRE 14C (2), S-1 (2), S-1/A (2), SC 13G (2), SC 13G/A (2), 1-A (1), 1-A-W (1), 1-A/A (1), 25-NSE (1), 253G3 (1), 4/A (1), 424B2 (1), 424B3 (1), 424B4 (1), 8-A12B (1), AW (1), CERT (1), D (1), NTN 10Q (1), QUALIF (1), REGDEX (1), RW (1), S-3/A (1), SB-2 (1), SEC STAFF ACTION (1)
- Latest filingsAnnual report (10-K) Dec 18, 2024
Quarterly report (10-Q) Jul 19, 2024
Proxy statement (DEF 14A) Oct 17, 2024
Latest 8-K (8-K) May 6, 2025
Risk factors and legal proceedings
The risks Novo Integrated Sciences, Inc. names in Item 1A of its 10-K filed Dec 18, 2024: 67 risks under these headings, as written.5
- History of operating losses and negative cash flow.
- Novo Integrated Sciences, Inc. is a parent company and depends upon our subsidiaries for our cash flows.
- Future acquisitions or strategic investments could disrupt our business and harm our business, results of operations or financial condition.
- We require additional funding for our growth plans, and such funding may result in a dilution of your investment.
- Most of our executive officers do not reside in the United State.
- Our future success depends on the continuing efforts of our key employees and our ability to attract, hire, retain and motivate highly skilled and creative employees in the future.
- We believe our corporate culture has contributed to our success and, if we are unable to maintain it as we grow, our business could be harmed.
- We may not have sufficient insurance coverage and an interruption of our business or loss of a significant amount of property could have a material adverse effect on our financial condition and operations.
- We could become involved in claims or litigation that may result in adverse outcomes.
- We may be unable to adequately safeguard our intellectual property or we may face claims that may be costly to resolve or that limit our ability to use such intellectual property in the future.
- We could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act and similar international anti-bribery and anti-kickback laws with respect to our activities outside the United States.
- We are subject to a number of risks related to credit card and debit card payments we accept.
The other 55 risks
- Security breaches of confidential customer information, in connection with our electronic processing of credit and debit card transactions, or confidential employee information may adversely affect our business.
- We rely on third parties to provide services in connection with our business, and any failure by these third parties to perform their obligations could have an adverse effect on our business, financial condition and results of operations.
- Our amended and rested articles of incorporation provide that the state or federal court located within the state of Nevada will be the sole and exclusive forum for substantially all disputes between us and our shareholders, which could limit its stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or other employees.
- Public health epidemics or outbreaks could adversely impact our business.
- Risks Related to our Multidisciplinary Primary Healthcare Business
- We may not be able to successfully implement our business growth initiatives for our multidisciplinary primary healthcare business on a timely basis or at all, which could harm our business, financial performance, financial position, and results of operations.
- The long-term success of our multidisciplinary primary healthcare business is highly dependent on our ability to successfully identify and acquire target clinics and identify and secure staffing opportunities.
- Our intended acquisition and opening of clinics and increase in staffing in new markets exposes us to various risks and may require us to develop new business models.
- We will require additional capital to fund our operating and expansion costs, and our inability to obtain such capital will likely harm our business.
- The clinics that we intend to acquire or open may not meet our expectations.
- If we open new clinics in existing markets, revenue at our existing clinics may be affected negatively.
- We may be required to make capital expenditures in connection with our acquisitions to implement our growth strategy.
- Damage to our reputation or our brand in existing or new markets could negatively impact our business, financial condition and results of operations.
- Our marketing activities may not be successful.
- The multidisciplinary primary healthcare market is highly competitive, including competition for patients, strategic relationships, and commercial payor contracts, each of which could adversely affect our contract and revenue base.
- We may not be able to recruit and retain qualified multidisciplinary primary healthcare clinicians for our multidisciplinary primary healthcare clinics and staffing of affiliate clinics and eldercare centric homes.
- We may not be able to prohibit or limit our multidisciplinary primary healthcare clinicians from competing with us in our local markets.
- With respect to our operations in Canada, we may be unable to enter into or maintain contracts for our affiliate multidisciplinary primary healthcare clinics and eldercare focused facilities or services on favorable terms with commercial payors.
- With respect to our anticipated expansion of our operations into the United States, we may be unable to enter into or maintain contracts for our multidisciplinary primary healthcare clinics and services on favorable terms with commercial payors in the United States.
- Government healthcare programs may reduce reimbursement rates.
- If payments from commercial or governmental payors are significantly delayed, are reduced or eliminated, our business, prospects, results of operations and financial condition could be adversely affected.
- Significant changes in our payor mix resulting from fluctuations in the types of patients seen at our clinics could have a material adverse effect on our business, prospects, results of operations and financial condition.
- Failure to bill timely or accurately for our services could have a negative impact on our net revenues, bad debt expense and cash flow.
- We are dependent on our third-party revenue cycle managers for billing and collection of our claims.
- We may incur costs resulting from security risks in connection with the electronic data processing by our partner banks.
- With respect to our Canadian operations and our anticipated expansion of our operations into the United States, a successful challenge by tax authorities to our treatment of certain multidisciplinary primary healthcare clinicians and practitioners as independent contractors or the elimination of an existing safe harbor could materially increase our costs relating to these multidimensional primary healthcare clinicians and practitioners.
- Currently, our corporate owned clinics and affiliate clinics are located in the Canadian provinces of Ontario, Alberta, Nova Scotia and Newfoundland making us particularly sensitive to regulatory, economic, and other conditions in those provinces.
- Our business is seasonal, which may impact results of operations.
- We could be subject to lawsuits for which we are not fully insured.
- Insurance coverage for some of our losses may be inadequate and may be subject to the credit risk of commercial insurance providers.
- Risks Related to Healthcare Regulation
- The healthcare industry is heavily regulated, and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations.
- Our Canadian clinics are and will be subject to numerous statutes and regulations. Additionally, given our intention to expand and begin operations in the United States, we will be subject to numerous U.S. statutes and regulations. Failure to comply with these laws and regulations could result in civil or criminal sanctions.
- With respect to our anticipated expansion of our operations into the United States, state regulation of the expansion of multidisciplinary primary healthcare clinics could prevent us from reaching our expansion objectives.
- Our services, and related products, are subject to comprehensive laws and regulations that govern the manner in which we bill and are paid for our services by third-party payors, and the failure to comply with these requirements can result in civil or criminal sanctions, including exclusion from federal and state healthcare programs.
- Changes in coverage and the rates or methods of third-party reimbursements may adversely affect our revenue and operations.
- Past and future legislation related to the healthcare industry and other changes in the healthcare industry could adversely affect our business, financial condition, and results of operations.
- We are subject to the Canada Health Act, Canada’s National Health Insurance Program and Food and Drugs Act and analogous provisions of applicable state laws and could face substantial penalties if we fail to comply with such laws.
- Federal/Provincial Government Division of Power in Canada
- Canada’s National Health Insurance Program
- The Canada Health Act
- Regulation of Health Professionals and Health Facilities
- Health Professionals
- Health Facilities
- Regulation of Drugs
- The Patented Medicines Prices Review Board
- Public Market Access
- We are subject to the data privacy and security laws of Canada, and the failure to comply with these rules, or allegations that we have failed to do so, could result in civil or criminal sanctions.
- Following the intended acquisition, or opening, of one or more clinics or staffing primary healthcare practitioners in the United States, our centers may participate in the federal Medicare program and, as a result, we will need to comply with a number of additional federal regulatory requirements.
- Following the intended acquisition, or opening, of one or more clinics or staffing primary healthcare practitioners in the United States, we will be subject to CMS’ RAC program.
- Following the intended acquisition, or opening, of one or more clinics or staffing primary healthcare practitioners in the United States, we will be subject to the Anti-Kickback Statute, FCA, Civil Monetary Penalties statute and analogous provisions of applicable state laws and could face substantial penalties if we fail to comply with such laws.
- Anti-Kickback Statute
- False Claims Act
- Civil Monetary Penalties Statute
- Following the intended acquisition, or opening, of one or more clinics or staffing primary healthcare practitioners in the United States, we will be subject to the data privacy, security and breach notification requirements of HIPAA, HITECH and other data privacy and security laws, and the failure to comply with these rules, or allegations that we have failed to do so, could result in civil or criminal sanctions.
- Following the intended acquisition, or opening, of one or more multidisciplinary primary healthcare clinics or the staffing of multidisciplinary primary healthcare clinics, affiliate clinics or eldercare centric homes with clinicians and practitioners in the United States, if we fail to effectively and timely implement electronic health record systems, our operation could be adversely affected.
- If we fail to comply with laws and regulations related to the protection of the environment and human health and safety, we could incur substantial penalties and fines.
- Risks Related to our Telemedicine Medical Technology Platform, RPM Medical Technology Platform and Novo Connect Medical Technology Platform
- We may be unsuccessful in the development, usage, application and commercialization of each or all of our Medical Technology Platforms.
- The success of our Medical Technology Platforms will be highly dependent upon our ability to develop relationships with both Canadian based and United States based medically licensed primary care providers and specialist in addition to multidisciplinary primary healthcare clinicians.
- Our Medical Technology Platforms may not be accepted in the Canadian and United States marketplace.
- Defects or malfunctions in our Medical Technology Platforms could hurt our reputation, sales and profitability.
- Software failures, breakdowns in the operations of our servers and communications systems or the failure to implement system enhancements could harm our business.
- We face risks related to the storage of customers’ and their end users’ confidential and proprietary information.
- We might incur substantial expense to further develop each or all of our Medical Technology Platforms which may never become sufficiently successful.
- We will be applying to obtain trademark and copyright protection, and possibly patent protection as applicable, but cannot guarantee we will obtain these applications and protections for each or all of our Medical Technology Platforms.
- Government regulation of the Internet and e-commerce is evolving, and unfavorable changes could substantially harm our business and results of operations.
- Risks Related to the United States Regulatory System as to Medicinal CBD Products
Legal proceedings
As of the filing date of this Annual Report on Form 10-K, there are no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which we are a party or which our property is the subject. In addition, none of our officers, directors, affiliates or 5% stockholders (or any associates thereof) is a party adverse to us, or has a material interest adverse to us, in any material proceeding.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17SEC EDGARChristopher Mehlin David, President
- 18
- 19
- 20SEC EDGARSarfaraz Ali, Board member
- 21SEC EDGARAlex Flesias, Board member
- 22SEC EDGARMichael Joseph Gaynor, Board member
- 23SEC EDGARPierre Joseph Dalcourt, Board member
- 24SEC EDGARRobert Letterio Oliva, Board member
- 25SEC EDGARExecutive or director change
- 26SEC EDGARListing notice or transfer
- 27SEC EDGARExecutive or director change
- 28SEC EDGARExecutive or director change
- 29SEC EDGARExecutive or director change
- 30SEC EDGARExecutive or director change
- 31SEC EDGARResults of operations
- 32SEC EDGARShareholder vote
- 33SEC EDGAROther events
- 34
- 35SEC EDGARListing notice or transfer
- 36SEC EDGARExecutive or director change
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44